Study of HS-10566 for high-risk bladder cancer without muscle involvement
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug (HS-10566) placed directly into the bladder for people with high-risk bladder cancer that hasn't reached the muscle. It's for those who cannot take or refuse bladder removal surgery, especially if standard BCG therapy didn't work well or isn't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and diagnosed with a type of bladder cancer that has not invaded the bladder muscle (called non-muscle-invasive bladder cancer).
- You must have had a procedure called TURBT (a surgery to remove visible tumors from the bladder) within the last 12 weeks.
- You either had BCG therapy (a standard bladder treatment) and it stopped working, or you cannot have BCG or have not had it for more than 3 years.
- You must be willing to not have the bladder-removal surgery (radical cystectomy) or your doctor says you cannot have it safely.
- You must be in fairly good overall health, able to perform daily activities without much help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Hear when a new High Risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.